featured
Extended Follow-Up of Multicenter Trial Demonstrates Continued Superiority of Bivalirudin to Heparin With and Without Glycoprotein IIb/IIIa Inhibition in Patients With Acute Myocardial Infarction
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: